See more : Entest Group, Inc. (ETNI) Income Statement Analysis – Financial Results
Complete financial analysis of Seer, Inc. (SEER) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Seer, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Huadian Power International Corporation Limited (HPIFY) Income Statement Analysis – Financial Results
- Greystone Logistics, Inc. (GLGI) Income Statement Analysis – Financial Results
- Canada Goose Holdings Inc. (GOOS) Income Statement Analysis – Financial Results
- Auden Techno Corp. (3138.TW) Income Statement Analysis – Financial Results
- Wong’s Kong King International (Holdings) Limited (0532.HK) Income Statement Analysis – Financial Results
Seer, Inc. (SEER)
About Seer, Inc.
Seer, Inc., a life sciences company, engages in developing and commercializing products to decode the secrets of the proteome. It develops Proteograph Product Suite, an integrated solution that comprises consumables, an automation instrumentation, and software that allows researchers to conduct proteomic studies in therapeutic and diagnostic research, and clinical trials. The company intends to sell its products for research purposes, which cover academic institutions, life sciences, and research laboratories, as well as biopharmaceutical and biotechnology companies for non-diagnostic and non-clinical purposes. It has a collaboration agreement with Discovery Life Sciences, LLC. and the Salk Institute for Biological Studies. The company was formerly known as Seer Biosciences, Inc. and changed its name to Seer, Inc. in July 2018. Seer, Inc. was incorporated in 2017 and is headquartered in Redwood City, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 15.18M | 14.69M | 6.39M | 656.00K | 58.00K | 0.00 |
| Cost of Revenue | 8.16M | 7.94M | 3.21M | 0.00 | 701.00K | 100.00K |
| Gross Profit | 7.03M | 6.74M | 3.19M | 656.00K | -643.00K | -100.00K |
| Gross Profit Ratio | 46.29% | 45.91% | 49.87% | 100.00% | -1,108.62% | 0.00% |
| Research & Development | 53.02M | 45.80M | 29.12M | 18.94M | 12.39M | 3.78M |
| General & Administrative | 0.00 | 0.00 | 0.00 | 15.36M | 4.61M | 2.98M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 58.95M | 58.53M | 45.76M | 15.36M | 4.61M | 2.98M |
| Other Expenses | 0.00 | -351.00K | -223.00K | -9.00K | -58.00K | 0.00 |
| Operating Expenses | 111.97M | 103.98M | 74.66M | 34.31M | 16.94M | 6.76M |
| Cost & Expenses | 120.12M | 111.92M | 77.87M | 34.31M | 16.94M | 6.76M |
| Interest Income | 17.76M | 4.60M | 326.00K | 883.00K | 850.00K | 451.00K |
| Interest Expense | 0.00 | 327.00K | 22.00K | 9.00K | 5.00K | 0.00 |
| Depreciation & Amortization | 5.58M | 5.90M | 3.56M | 1.61M | 701.00K | 100.00K |
| EBITDA | -97.89M | -93.29M | -68.59M | -31.17M | -15.33M | -6.21M |
| EBITDA Ratio | -644.74% | -633.07% | -1,112.72% | -4,994.82% | -26,434.48% | 0.00% |
| Operating Income | -103.46M | -97.24M | -71.47M | -33.65M | -16.88M | -6.76M |
| Operating Income Ratio | -681.48% | -662.14% | -1,117.81% | -5,129.42% | -29,108.62% | 0.00% |
| Total Other Income/Expenses | 17.19M | 4.27M | 304.00K | 874.00K | 845.00K | 451.00K |
| Income Before Tax | -86.28M | -92.97M | -71.17M | -32.78M | -16.04M | -6.31M |
| Income Before Tax Ratio | -568.28% | -633.07% | -1,113.06% | -4,996.19% | -27,651.72% | 0.00% |
| Income Tax Expense | 0.00 | -4.27M | -2.54M | -1.61M | 5.00K | 451.00K |
| Net Income | -86.28M | -88.70M | -68.63M | -31.17M | -16.04M | -6.31M |
| Net Income Ratio | -568.28% | -604.00% | -1,073.40% | -4,751.37% | -27,660.34% | 0.00% |
| EPS | -1.35 | -1.42 | -1.13 | -0.51 | -0.26 | -0.29 |
| EPS Diluted | -1.35 | -1.42 | -1.13 | -0.51 | -0.26 | -0.29 |
| Weighted Avg Shares Out | 63.85M | 62.43M | 60.86M | 60.91M | 60.91M | 21.45M |
| Weighted Avg Shares Out (Dil) | 63.85M | 62.43M | 60.86M | 60.91M | 60.91M | 21.45M |
Seer, Inc. (SEER) Reports Q1 Loss, Tops Revenue Estimates
Seer to Present at the BofA Securities 2022 Healthcare Conference
Seer to Report First Quarter Financial Results on May 4, 2022
Seer, Inc. (SEER) CEO Omid Farokhzad on Q4 2021 Results - Earnings Call Transcript
Seer to Present at the Cowen 42nd Annual Health Care Conference
Seer to Present Virtually at the 40th Annual J.P. Morgan Healthcare Conference
Seer, Inc. (SEER) CEO Omid Farokhzad on Q3 2021 Results - Earnings Call Transcript
Seer: First Pick In Proteomics Portfolio
Seer to Present at the Morgan Stanley Global Healthcare Conference
Seer, Inc.'s (SEER) CEO Omid Farokhzad on Q2 2021 Results - Earnings Call Transcript
Source: https://incomestatements.info
Category: Stock Reports